Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05200364 · ClinicalTrials.gov registry record · Phase 1
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
A Phase 1 study, sponsored by Sutro Biopharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT05200364 is a Phase 1 study that was terminated before completion, run by Sutro Biopharma. The registered enrollment target is 58 participants.
The verdict
NCT05200364, a Phase 1 study, was terminated before completion, sponsored by Sutro Biopharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
Interventions
- DRUG Bevacizumab
- DRUG STRO-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05200364
The ClinicalTrials.gov registry entry for NCT05200364 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sutro Biopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT05200364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05200364 about?
NCT05200364 is a clinical study titled "A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer". Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
What is the current status of trial NCT05200364?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2022-03-22. Estimated completion is 2025-06-01.
What interventions are being tested in trial NCT05200364?
The interventions under investigation include: Bevacizumab (DRUG), STRO-002 (DRUG).
Who is sponsoring clinical trial NCT05200364?
This trial is sponsored by Sutro Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.